The study of the mechaniem of bronchial heperresponsiveness the effect of inflammatory cytokines on autononic receptors

支气管高反应性机制及炎症细胞因子对自主受体影响的研究

• 批准号: 12670546
• 负责人: SHIOYA Takanobu
• 金额: $ 2.05万
• 依托单位: Akita University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670546/
• 关键词: Bronchial Asthma; Cytokine inhibitor; Bronchial hyperresponsiveness; Cough Receptors; Positron emission tomography; Muscarinic receptor; ポジトロンエミッショントモグラフィー; ポジトロンエミッショントモグラフィ

As a clinical research, we measured the ntunber of eosinopils and eosinophil cationic protein (ECP) in the sputum of the patients with bronchial asthma and we compared these data with bronchial hyperresponsiveness, pulmonary functions and their symptoms. We measured the same factors before and after administration of suplatast tosilate (IPD), a Th2 cytokine inhibitor. We also evaluated capsaicin cough threshold, the cough scores and the therapeutic scores. _As results, increased bronchial hyperresponsiveness, small airway diseases and increased ECP concentrations were observed in the patients with bronchial asthma. After administration of IPD cough was decreased and couth threshold improved significantly in thepatients with bronchial asthma. These results were published at the Japanese Society of Allergology Meeting (March 21 to 23, 2002. Makuhari, Chiba, Japan), and will be published at the 97th-ATS meeting (May 19 to 22, 2002, Atlanta, USA).As a basic research, we evaluated the visualization of muscarinic receptors by using positron emission tomography (PET). 11[C]3NMPB, muscarinic receptor antagonist was administered into the vein and body metabolism and distribution were measured and radioactivity in the lungs was counted. Radioactivity of 11[C]3NMPB were detected highly in both lungs suggesting existence of abundant muscarinic receptors in human lung. The part of these results will be publishd at the 42nd Japanese Respiratory Meeting (April 4 to 6, 2002, Sendai) and at the 97th ATS meeting (May 19 to 22, 2002, Atlanta, USA).

作为一项临床研究，我们测定了支气管哮喘患者痰液中嗜酸性粒细胞（EOS）和嗜酸性粒细胞阳离子蛋白（ECP）的含量，并与支气管高反应性、肺功能及症状进行了比较。我们测量了相同的因素之前和之后的甲磺司特（IPD），Th2细胞因子抑制剂管理。并对辣椒碱咳嗽阈值、咳嗽评分和治疗评分进行了评价。结果表明，支气管哮喘患者存在气道高反应性、小气道病变和ECP浓度增高。IPD治疗后，支气管哮喘患者咳嗽明显减少，咳嗽阈值明显提高。这些结果发表在日本变态反应学会会议（2002年3月21日至23日）上。Makuhari，千叶，日本），并将在第97届ATS会议（2002年5月19日至22日，美国亚特兰大）上发表。经静脉给予毒蕈碱受体拮抗剂11[C]3NMPB，测量体内代谢和分布，并计数肺中的放射性。11[C]3NMPB放射性在两肺均较高，提示人肺中存在丰富的毒蕈碱受体。这些结果的一部分将在第42届日本呼吸会议（2002年4月4日至6日，仙台）和第97届ATS会议（2002年5月19日至22日，美国亚特兰大）上公布。

项目成果

塩谷隆信: "咳喘息に対するTh_2サイトカイン阻害薬の効果"New Insights into Asthma and Allergies. 1. 5 (2000)

Takanobu Shioya：“Th_2 细胞因子抑制剂对咳嗽哮喘的影响”《哮喘和过敏的新见解》1. 5 (2000)。

塩谷隆信: "呼吸器疾患専門医に開く最新の臨床"工藤翔二,永井厚志編集,中外医学社. 271 (2000)

Takanobu Shioya：“呼吸系统疾病专家的最新临床实践”，由 Shoji Kudo 和 Atsushi Nagai 编辑，Chugai Igakusha 271 (2000)。

塩谷隆信: "気管支喘息:吸入抗コリン薬の適応と限界"Medicina. 39・1. 34-36 (2002)

Takanobu Shioya：“支气管哮喘：吸入抗胆碱能药物的适应症和局限性”Medicina 39・1（2002）。

Takanobu Shioya, et al.: "β^2 adrenoreceptor stimuleting tape."Asthma. 14(4). 83-89 (2001)

Takanobu Shioya 等人：“β^2 肾上腺素受体刺激胶带”14(4) (2001)。

Takanobu Shioya: "Respiratory Physiotherapy"Todays Therapy 2002. 1527 (2002)

Takanobu Shioya：“呼吸物理治疗”Todays Therapy 2002. 1527 (2002)